

Sunstone Life Science Ventures divests its holding in Arcoma AB

Copenhagen, Denmark, December 20, 2023 – Sunstone Life Science Ventures (“**Sunstone**”), a leading Nordic venture capital firm, announces that one hundred percent of the holding in Arcoma AB (“**Arcoma**”) have been sold in a structured block sale.

Sunstone has been a major owner in Arcoma since 2010 and is proud of what the company has achieved in delivering world-class digital radiographic systems. The investment was placed in Sunstone Life Science Venture Funds II established in 2007. The fund is under liquidation and the divestment is a step in the process to return proceeds to the investors in the Fund and is in no way related to the current status or progress of Arcoma.

The transaction was executed as a block sale, coordinated by Sedermera Corporate Finance AB, outside of the stock market. The sale includes all of Sunstone’s shareholding, corresponding to 2 355 481 and shares 17.9 percent of the capital. The buyers were a consortium of existing shareholders in Arcoma such as Linc AB, chairman Lars Kvarnhem via company and new investors to Arcoma.

Søren Lemonius, Managing Partner, comment:

“We are proud of the role we have played in the development of Arcoma and also impressed by how the company has continued to improve sales performance recently. The good progress has supported a renewed interest from investors to increase shareholdings or become new shareholders and it has allowed Sunstone to divest all shares in one transaction. We are not shareholders anymore, but after 13 years of ownership, I am sure we will continue to track the progress of the company and we wish all the best for Arcoma in the years to come.

Bookrunner

Sedermera Corporate Finance AB acted as Sole Manager and Bookrunner in the Block Sale.

About Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since inception, Sunstone has invested in more than 60 companies, and has completed more than 25 successful IPOs and large M&A transactions.

For more information about Sunstone, please visit sunstone.eu